Day One Biopharmaceuticals, Inc vs Merck & Company, Inc. — Stock Comparison
Day One Biopharmaceuticals, Inc (DAWN) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. holds a significant lead over Day One Biopharmaceuticals, Inc on Q·Score (7 vs 4.5 out of 10), led by Quality (7.7 vs 0.5) and Sentiment (7.1 vs 2.5). Day One Biopharmaceuticals, Inc scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for MRK (+13.9%) than for DAWN (-0.1%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-68% margin).
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
DAWN vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Day One Biopharmaceuticals, Inc (DAWN) at 4.5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: DAWN or MRK?
Day One Biopharmaceuticals, Inc (DAWN) scores higher on Growth (7.3/10 vs 6.2/10). Day One Biopharmaceuticals, Inc reports revenue growth (83.9% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is DAWN or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.7/10 vs 3.7/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about DAWN vs MRK?
There are 6 analysts covering DAWN with a consensus price target of $21.50, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: DAWN or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 0.5/10). Net profit margin: DAWN at -67.8%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: DAWN or MRK?
Day One Biopharmaceuticals, Inc (DAWN) scores higher on Financial Health (9.2/10 vs 7/10). Market beta: DAWN at -1.75, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of DAWN and MRK?
Day One Biopharmaceuticals, Inc (DAWN) has a market capitalisation of $2.2B, while Merck & Company, Inc. (MRK) has a market cap of $281.2B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do DAWN or MRK pay dividends?
DAWN does not currently pay a dividend, while MRK pays a dividend yield of 2.95%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →